Fusobacterium necrophorum: Difference between revisions

From IDWiki
Fusobacterium necrophorum
Content deleted Content added
Created page with "{{DISPLAYTITLE:''Fusobacterium necrophorum''}} == Background == * Anaerobic Stain::Gram-negative or Stain::Gram-variable Shape::bacillus within the genus Genus::Fusobacterium * Previously known as ''Bacillus necrophorus'' == Clinical Manifestations == * Odontogenic infections * Causative organism of Lemierre syndrome * Can spread hematogenously to bone and joint, muscles and soft tissue, liver, spleen, and endoc..."
 
No edit summary
 
Line 17: Line 17:


* First-line options include [[piperacillin-tazobactam]], carbapenems, and [[metronidazole]]
* First-line options include [[piperacillin-tazobactam]], carbapenems, and [[metronidazole]]
** Often need polymicrobial coverage, for this [[ceftriaxone]] plus [[metronidazole]] would be an excellent option
* May produce beta-lactamases, so shouldn't use penicillins without beta-lactamase inhibitors
* Patients with [[Lemierre syndrome]] can take more than a week to defervesce, despite appropriate antibiotics


== Further Reading ==
== Further Reading ==

Latest revision as of 14:34, 17 February 2026


Background

  • Anaerobic Gram-negative or Gram-variable bacillus within the genus Fusobacterium
  • Previously known as Bacillus necrophorus

Clinical Manifestations

  • Odontogenic infections
  • Causative organism of Lemierre syndrome
  • Can spread hematogenously to bone and joint, muscles and soft tissue, liver, spleen, and endocarditis
  • Can cause peritonsillar abscess, deep neck space infections, and mediastinitis
  • Has been implicated in venous sinus thrombophlebitis, meningitis, and brain abscess (the latter more often in polymicrobial infection and more commonly involves Fusobacterium nucleatum)

Management

Further Reading

  • Human Infection with Fusobacterium necrophorum (Necrobacillosis) with a Focus on Lemierre Syndrome. Clin Microbiol Rev. 2007;20(4):622-659. doi 10.1128/CMR.00011-07